Trial Profile
Influence of Exceptional Patient Characteristics on Everolimus Exposure
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Feb 2022
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Advanced breast cancer
- Focus Pharmacokinetics
- Acronyms INPRES
- 27 Sep 2018 Results published in the Targeted Oncology
- 05 Jun 2018 Results (n=44) assessing everolimus exposure and early metabolic response as predictors for treatment outcomes, presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 11 Apr 2018 Status changed from active, no longer recruiting to completed.